Platelet aggregation is inhibited for roughly 7-10 days when COX-1 is inhibited (average platelet lifespan). It is non selective for COX-1 and COX-2 enzymes. Thromboxane A2 is a lipid that causes platelet aggregation, which can lead to clot formation and an increased risk of heart attack or stroke in the future.Īcetylsalicylic acid (ASA) inhibits the production of prostaglandins. Platelet aggregation is inhibited by ASA due to its interference with thromboxane A2 in platelets, which is induced by COX-1 suppression. Prostaglandin E1 is well-known for being a potent fever-inducing substance. Because of its potential to inhibit the formation of brain prostaglandin E1, acetylsalicylic acid is considered an antipyretic. This medicine may prohibit prostaglandins from acting on pain receptors by disrupting their manufacture and preventing their release in inflammation. Prostaglandins make pain receptors and chemicals like histamine and bradykinin more sensitive. Prostaglandins are powerful irritants that have been demonstrated to produce headaches and pain in people when injected.

Acetylsalicylic acid or aspirin inhibits the production of prostaglandins in the body by targeting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). To avoid thrombosis at the insertion site of a silicone rubber arteriovenous cannula in patients receiving hemodialysis.To reduce platelet to platelet adhesion and prevent transient ischemic attacks (TIA), after carotid endarterectomy.To prevent thromboembolism, after hip replacement surgery.To reduce the risk of transient ischemic attacks (TIA) and to avoid atherothrombotic cerebral infarction, In conjunction with other treatments.To lower the risk of a first non-fatal myocardial infarction in patients, as well as morbidity and mortality in patients with unstable angina and those who have experienced a previous myocardial infarction.To lower the risk of cardiovascular death in suspected myocardial infarction cases.

Aspirin poisoning antidote